Skip Nav Destination
Close Modal
Search Results for
glp-1-glucagon-peptide-1-0
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Journal
Article Type
Topics
Subjects
Issue Section
Date
Availability
1-20 of 623 Search Results for
glp-1-glucagon-peptide-1-0
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Meeting Abstracts
PREESHILA BEHARY, GEORGE THARAKAN, KLEOPATRA ALEXIADOU, NICHOLAS A. JOHNSON, NICOLAI JACOB WEWER ALBRECHTSEN, JOYCELINE CUENCO, DAVID HOPE, WALJIT DHILLO, JAMES S. MINNION, GARY FROST, CAREL LE ROUX, SANJAY PURKAYASTHA, KRISHNA MOORTHY, JENS J. HOLST, AHMED AHMED, TOBY PREVOST, STEPHEN BLOOM, TRICIA M.M. TAN
Journal:
Diabetes
Diabetes 2019;68(Supplement_1):57-OR
Published: 01 June 2019
...; TRICIA M.M. TAN Background: Roux-en-Y gastric bypass (RYGB) is a successful treatment for diabetes and obesity, possibly because it augments post-prandial secretion of the gut hormones glucagon-like peptide-1 (GLP-1), oxyntomodulin (OXM) and peptide YY (PYY). Subcutaneous infusion of GLP-1, OXM and PYY...
Meeting Abstracts
TAKAHIRO KAWAI, FUMIHITO TANINO, MASANORI FUKAZAWA, KOTARO OGAWA, SHUNSUKE NAGAO, HITOSHI YOSHINO, SHUN-ICHIRO KOMATSU, YOSHIYUKI SUZUKI, YOSHIKI KAWABE
Journal:
Diabetes
Diabetes 2018;67(Supplement_1):1118-P
Published: 01 July 2018
...TAKAHIRO KAWAI; FUMIHITO TANINO; MASANORI FUKAZAWA; KOTARO OGAWA; SHUNSUKE NAGAO; HITOSHI YOSHINO; SHUN-ICHIRO KOMATSU; YOSHIYUKI SUZUKI; YOSHIKI KAWABE Activation of glucagon-like peptide-1 receptors (GLP-1R) is a promising approach for the treatment of type 2 diabetes mellitus (T2D), and several...
Meeting Abstracts
ALEXANDER S. CHRISTENSEN, SOFIE HAEDERSDAL, HEIDI STORGAARD, KATHRINE ROSE, NINA L. HANSEN, JENS J. HOLST, TORBEN HANSEN, FILIP K. KNOP, VILSBØLL TINA
Journal:
Diabetes
Diabetes 2019;68(Supplement_1):981-P
Published: 01 June 2019
... control. In a randomized, double-blinded, cross-over study, we evaluated the insulinotropic effect of exogenous glucose-dependent insulinotropic peptide (GIP) and glucagon-like-peptide 1 (GLP-1), respectively, with and without SU in patients with HNF1A-diabetes. Ten patients with HNF1A-diabetes ([mean±SD...
Meeting Abstracts
MARIA D. HURTADO, AOIFE M. EGAN, MARCELLO C. LAURENTI, J.D. ADAMS, ROBERT A. RIZZA, CLAUDIO COBELLI, ALEKSEY MATVEYENKO, CHIARA DALLA MAN, ADRIAN VELLA
Journal:
Diabetes
Diabetes 2019;68(Supplement_1):1839-P
Published: 01 June 2019
...MARIA D. HURTADO; AOIFE M. EGAN; MARCELLO C. LAURENTI; J.D. ADAMS; ROBERT A. RIZZA; CLAUDIO COBELLI; ALEKSEY MATVEYENKO; CHIARA DALLA MAN; ADRIAN VELLA Glucagon-Like Peptide-1 (GLP-1) potentiates insulin secretion in response to an oral challenge. Exendin-(9,39) a competitive antagonist of GLP-1...
Images
in Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans
> Diabetes
Published: 23 April 2011
FIG. 1. Plasma concentrations of GLP-1 (A), glucose (C), insulin (D), glucagon (E), C-peptide (F), PP (G), and GIP (H), and gastric emptying (B) after instilling two liquid test meals (amino acids and sucrose) via a nasogastric tube into the stomach at 0 and 240 min in nine healthy young volunteers during the intravenous infusion of GLP-1 (0.8 pmol · kg−1 ⋅ min−1) or placebo. Mean ± SEM. P values were calculated by repeated-measures ANOVA. *Significant (P < 0.05) differences at specific time points between experiments with placebo and GLP-1. †Significant difference from the corresponding time point after the first meal during the exogenous administration of GLP-1. FIG. 1. Plasma concentrations of GLP-1 (A), glucose (C), insulin (D), glucagon (E), C-peptide (F), PP (G), and GIP (H), and gastric emptying (B) after instilling two liquid test meals (amino acids and sucrose) via a nasogastric tube into the stomach at 0 and 240 min in nine healthy young volunteers during the intravenous infusion of GLP-1 (0.8 pmol · kg−1 ⋅ min−1) or placebo. Mean ± SEM. P values were calculated by repeated-measures ANOVA. *Significant (P < 0.05) differences at specific time points between experiments with placebo and GLP-1. †Significant difference from the corresponding time point after the first meal during the exogenous administration of GLP-1. More
Journal Articles
Lærke S. Gasbjerg, Mads M. Helsted, Bolette Hartmann, Mette H. Jensen, Maria B.N. Gabe, Alexander H. Sparre-Ulrich, Simon Veedfald, Signe Stensen, Amalie R. Lanng, Natasha C. Bergmann, Mikkel B. Christensen, Tina Vilsbøll, Jens J. Holst, Mette M. Rosenkilde, Filip K. Knop
Journal:
Diabetes
Diabetes 2019;68(5):906–917
Published: 09 January 2019
... glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted postprandially and contribute importantly to postprandial glucose tolerance. In this study, we assessed the individual and combined contributions of endogenous GIP and GLP-1 to the postprandial changes...
Journal Articles
Journal:
Diabetes
Diabetes 2005;54(7):2212–2218
Published: 01 July 2005
... in addition to GLP-1. A liquid test meal (50 g sucrose and 8% mixed amino acids in 400 ml) was administered at 0 min. Capillary and venous blood samples were drawn for the determination of glucose (glucose oxidase), insulin, C-peptide, GLP-1, glucagon, gastric inhibitory polypeptide (GIP), and pancreatic...
Meeting Abstracts
MICHAEL FRALICK, SEOYOUNG C. KIM, SEBASTIAN SCHNEEWEISS, BRENDAN M. EVERETT, ROBERT J. GLYNN, ELISABETTA PATORNO
Journal:
Diabetes
Diabetes 2019;68(Supplement_1):1539-P
Published: 01 June 2019
...-matched to patients newly prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist. The primary outcome was lower-limb amputation requiring surgery. Hazard ratios (HR) and 95% confidence intervals (CI) were computed for the risk of subsequent amputation among patients <65 and ≥65 years old. We...
Meeting Abstracts
DALE S. EDGERTON, GUILLAUME KRAFT, MARTA S. SMITH, L. MERKLE MOORE, BEN FARMER, HEATHER SARA, MELANIE SCOTT, MARY MOORE, MICHAEL A. NAUCK, ALAN D. CHERRINGTON
Journal:
Diabetes
Diabetes 2018;67(Supplement_1):1961-P
Published: 01 July 2018
... responses were ∼25% greater in the OGTT compared to the other treatments, whereas there was <5% difference in their levels in Po vs. Pe. Arterial glucagon fell modestly in all treatments. Oral glucose administration increased arterial GLP-1 and GIP levels by >6-fold over basal, but their levels did...
Journal Articles
John Dupre, Margaret T Behme, Irene M Hramiak, Philip McFarlane, M Paul Williamson, Pamela Zabel, Thomas J McDonald
Journal:
Diabetes
Diabetes 1995;44(6):626–630
Published: 01 June 1995
.... Paul Williamson, Pamela Zabel, and Thomas J. McDonald Effects of human glucagon-like peptide I (GLP-I)(7- 36)amide were examined in volunteers having insulin- Gdependent diabetes mellitus (IDDM) with residual C-peptide (CP) secretion (« = 8,7 men and 1 woman; age, astric inhibitory polypeptide (GIP...
Meeting Abstracts
BRITTA GOEBEL, MICHELE SCHIAVON, ROBERTO VISENTIN, MICHELA RIZ, CHIARA DALLA MAN, CLAUDIO COBELLI, THOMAS KLABUNDE
Journal:
Diabetes
Diabetes 2018;67(Supplement_1):72-OR
Published: 01 July 2018
...BRITTA GOEBEL; MICHELE SCHIAVON; ROBERTO VISENTIN; MICHELA RIZ; CHIARA DALLA MAN; CLAUDIO COBELLI; THOMAS KLABUNDE SAR425899 (SAR) is a novel dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. A randomized, double-blind, phase I multiple-ascending-dose study (NCT02411825...
Meeting Abstracts
HANA KAHLEOVA, ANDREA TURA, MARTA KLEMENTOVA, LENKA BELINOVA, MARTIN HALUZIK, RENATA PAVLOVICOVA, MARTIN HILL, TEREZIE PELIKANOVA
Journal:
Diabetes
Diabetes 2019;68(Supplement_1):755-P
Published: 01 June 2019
... secretion in participants with type 2 diabetes (T2D). Research Design and Methods: A randomized crossover design was used in 20 participants with T2D. Plasma concentrations of glucose, insulin, C-peptide, glucagon-like peptide -1 (GLP-1), amylin, and gastric inhibitory peptide (GIP) were determined at 0...
Meeting Abstracts
Journal:
Diabetes
Diabetes 2020;69(Supplement_1):931-P
Published: 01 June 2020
... of optimal treatment choice, comparing intensification with additional oral antidiabetic drug (OAD), glucagon-like peptide-1 (GLP-1) analogs or insulin in individuals on 2 OADs. Methods: Electronic medical records and claims data were from IBM MarketScan Explorys Claims-EMR (index period: 3/1/13-10/31/18...
Meeting Abstracts
TAKAAKI MURAKAMI, HIROYUKI FUJIMOTO, NAOTAKA FUJITA, KEITA HAMAMATSU, JUNJI FUJIKURA, NOBUYA INAGAKI
Journal:
Diabetes
Diabetes 2019;68(Supplement_1):1969-P
Published: 01 June 2019
...TAKAAKI MURAKAMI; HIROYUKI FUJIMOTO; NAOTAKA FUJITA; KEITA HAMAMATSU; JUNJI FUJIKURA; NOBUYA INAGAKI Aims: For the purpose of visualization and quantification of β cells, glucagon-like peptide 1 receptor (GLP-1R)-targeting imaging including single photon emission computed and positron emission...
Meeting Abstracts
1326-P: Metformin Increases GLP-1 Concentrations and Improves Glycemia in Youth with Type 2 Diabetes
CELESTE K. CRAVALHO, ABBY G. MEYERS, LILIAN MABUNDO, AMBER B. COURVILLE, SHANNA BERNSTEIN, YUHAI DAI, MARY WALTER, SHAJI CHACKO, MOREY W. HAYMOND, STEPHANIE T. CHUNG
Journal:
Diabetes
Diabetes 2019;68(Supplement_1):1326-P
Published: 01 June 2019
.... Recent data suggests a primary role for the entero-insular instead of the gluconeogenic pathway, but there is no data in youth, in whom metformin efficacy is ∼50%. Our objectives were to: (1) compare incretin concentrations, glucagon-like 1 peptide (GLP-1) and gastric inhibitory polypeptide (GIP) in 12...
Meeting Abstracts
Journal:
Diabetes
Diabetes 2018;67(Supplement_1):1086-P
Published: 01 July 2018
...LANA C. PINTO; DIMITRIS V. RADOS; MARIANA R. FALCETTA; CRISTIANE B. LEITAO Background: Glucagon-like peptide-1 (GLP-1) receptors were identified in both acinar and ductal cells of pancreas. Animal studies suggested an association of GLP-1 agonists use and pancreatic premalignant changes. Randomized...
Meeting Abstracts
Journal:
Diabetes
Diabetes 2019;68(Supplement_1):1033-P
Published: 01 June 2019
...JINGYAN CHEN; QIN SUN; MIN ZHANG; HAOMING TIAN; SHU CHEN Objective: Polycystic ovary syndrome (PCOS) is one the most common metabolic and endocrine disorders in women, which is always accompanied with obesity and insulin resistance (IR). Glucagon-like peptide-1 (GLP-1) has been investigated...
Meeting Abstracts
Journal:
Diabetes
Diabetes 2018;67(Supplement_1):414-P
Published: 01 July 2018
...OSAMAH ALFAYEZ; MAJED S. AL YAMI; RAZAN ALSHEIKH Background: The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) was recently published. Thus, we here present a mixed treatment comparison meta-analysis (MTC) of major randomized clinical trials to determine Glucagon like peptide 1 (GLP-1...
Journal Articles
Journal:
Diabetes
Diabetes 1993;42(5):658–661
Published: 01 May 1993
...- bolic clearance rates of the two peptides. The effects of GLP-1 7-36 amide and GLP-1 7-37 on FIG. 2. Plasma concentrations of glucose (A), C-peptide (B), insulin 60 120 180 min (C), and glucagon (0) before, during, and after Intravenous Infusion of either GLP-1 7-36 amide ( ) or GLP-1 7-37 ( ). Mean...
Meeting Abstracts
JIRI VELEBA, MARTA KLEMENTOVA, LENKA BELINOVA, MARTIN HALUZIK, RENATA PAVLOVICOVA, MARTIN HILL, TEREZIE PELIKANOVA, HANA KAHLEOVA
Journal:
Diabetes
Diabetes 2019;68(Supplement_1):1914-P
Published: 01 June 2019
... participants (O, n=20), and healthy controls (H, n=20). Plasma concentrations of glucagon-like peptide -1 (GLP-1), amylin, and peptide YY (PYY) were determined at 0, 30, 60, 120 and 180 minutes. Satiety was assessed using a visual analogue scale. Repeated-measures ANOVA was used for statistical analysis...